Abstract | BACKGROUND: PATIENTS AND METHODS: 830 patients with advanced/metastatic or recurrent NSCLC who received palliative chemotherapy were retrospectively reviewed. Using a matched-pair case-control study design, 334 pairs from the pre- gefitinib era (January 1999 to December 2001) and the post- gefitinib era (January 2002 to December 2005) were matched by age, sex and histology. RESULTS: The median overall survival from the date of first administration of palliative chemotherapy was significantly longer in the post- gefitinib era (11.5 vs. 19.3 months, p< 0.001). Multivariate analysis showed that gefitinib was associated with longer overall survival (hazard ratio 0.58, p< 0.001) as were never having been a smoker, adenocarcinoma histology, good performance, stage IIIB, >or=3 prior episodes of chemotherapy, platinum-based chemotherapy and previous docetaxel or pemetrexed treatment. Patients in the post- gefitinib era showed significantly longer overall survival in almost all subgroups. Gefitinib treatment was of significantly greater benefit in patients with adenocarcinoma than in those with non- adenocarcinoma (test for interaction p< 0.001). CONCLUSION: These results indicate a significant improvement of survival in advanced NSCLC patients treated with gefitinib in Korea.
|
Authors | Hyo Song Kim, Keunchil Park, Hyun Jung Jun, Seong Yoon Yi, Jeeyun Lee, Jin Seok Ahn, Yeon Hee Park, Seonwoo Kim, Sangcheol Lee, Myung-Ju Ahn |
Journal | Oncology
(Oncology)
Vol. 76
Issue 4
Pg. 239-46
( 2009)
ISSN: 1423-0232 [Electronic] Switzerland |
PMID | 19246948
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright 2009 S. Karger AG, Basel. |
Chemical References |
- Antineoplastic Agents
- Quinazolines
- ErbB Receptors
- Gefitinib
|
Topics |
- Adult
- Aged
- Aged, 80 and over
- Antineoplastic Agents
(therapeutic use)
- Carcinoma, Non-Small-Cell Lung
(drug therapy, mortality)
- Case-Control Studies
- ErbB Receptors
(antagonists & inhibitors)
- Female
- Gefitinib
- Humans
- Lung Neoplasms
(drug therapy, mortality)
- Male
- Middle Aged
- Quinazolines
(therapeutic use)
|